These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 33464780)

  • 1. The role of anthranilic acid in the increase of depressive symptoms and major depressive disorder during treatment for hepatitis C with pegylated interferon-α2a and oral ribavirin.
    Pawlowski T; Pawlak D; Inglot M; Zalewska M; Marciniak D; Bugajska J; Janocha-Litwin J; Malyszczak K
    J Psychiatry Neurosci; 2021 Jan; 46(1):E166-E175. PubMed ID: 33464780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in the metabolism of tryptophan in patients with chronic hepatitis C six months after pegylated interferon-α 2a treatment.
    Pawlowski T; Malyszczak K; Inglot M; Zalewska M; Radkowski M; Laskus T; Pawlak D
    Psychoneuroendocrinology; 2018 Nov; 97():1-7. PubMed ID: 29990677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HTR1A, TPH2, and 5-HTTLPR Polymorphisms and Their Impact on the Severity of Depressive Symptoms and on the Concentration of Tryptophan Catabolites during Hepatitis C Treatment with Pegylated Interferon-α2a and Oral Ribavirin (PEG-IFN-α2a/RBV).
    Pawlowski T; Malyszczak K; Pawlak D; Inglot M; Zalewska M; Grzywacz A; Radkowski M; Laskus T; Janocha-Litwin J; Frydecka D
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C.
    Comai S; Cavalletto L; Chemello L; Bernardinello E; Ragazzi E; Costa CV; Bertazzo A
    Pharmacol Res; 2011 Jan; 63(1):85-92. PubMed ID: 20940053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of interferon alpha immunotherapy on tryptophan metabolism in patients with chronic hepatitis C. Results of a pilot studies on ten patients].
    Vignau J; Costisella O; Canva V; Imbenotte M; Duhamel A; Lhermitte M
    Encephale; 2009 Oct; 35(5):477-83. PubMed ID: 19853722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.
    Wichers MC; Koek GH; Robaeys G; Verkerk R; Scharpé S; Maes M
    Mol Psychiatry; 2005 Jun; 10(6):538-44. PubMed ID: 15494706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system.
    Bonaccorso S; Marino V; Puzella A; Pasquini M; Biondi M; Artini M; Almerighi C; Verkerk R; Meltzer H; Maes M
    J Clin Psychopharmacol; 2002 Feb; 22(1):86-90. PubMed ID: 11799348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A biopsychosocial model of interferon-alpha-induced depression in patients with chronic hepatitis C infection.
    Baranyi A; Meinitzer A; Stepan A; Putz-Bankuti C; Breitenecker RJ; Stauber R; Kapfhammer HP; Rothenhäusler HB
    Psychother Psychosom; 2013; 82(5):332-40. PubMed ID: 23942342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
    Doolin K; Allers KA; Pleiner S; Liesener A; Farrell C; Tozzi L; O'Hanlon E; Roddy D; Frodl T; Harkin A; O'Keane V
    Psychoneuroendocrinology; 2018 Sep; 95():8-17. PubMed ID: 29787958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment.
    Zignego AL; Cozzi A; Carpenedo R; Giannini C; Rosselli M; Biagioli T; Aldinucci A; Laffi G; Moroni F
    Dig Liver Dis; 2007 Sep; 39 Suppl 1():S107-11. PubMed ID: 17936210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Metabolic Profiles of the Tryptophan-Kynurenine Pathway in the high risk subjects of major depressive disorder.
    Sakurai M; Yamamoto Y; Kanayama N; Hasegawa M; Mouri A; Takemura M; Matsunami H; Miyauchi T; Tokura T; Kimura H; Ito M; Umemura E; Boku AS; Nagashima W; Tonoike T; Kurita K; Ozaki N; Nabeshima T; Saito K
    Sci Rep; 2020 Feb; 10(1):1961. PubMed ID: 32029791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation.
    Maes M; Mihaylova I; Ruyter MD; Kubera M; Bosmans E
    Neuro Endocrinol Lett; 2007 Dec; 28(6):826-31. PubMed ID: 18063923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN.
    Vabo IL; Ferreira LE; Pace FH
    Arq Gastroenterol; 2016; 53(1):20-4. PubMed ID: 27281500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection.
    Mahajan S; Avasthi A; Grover S; Chawla YK
    J Psychosom Res; 2014 Aug; 77(2):109-15. PubMed ID: 25077851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms?
    Quak J; Doornbos B; Roest AM; Duivis HE; Vogelzangs N; Nolen WA; Penninx BW; Kema IP; de Jonge P
    Psychoneuroendocrinology; 2014 Jul; 45():202-10. PubMed ID: 24845191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Species differences in L-tryptophan-kynurenine pathway metabolism: quantification of anthranilic acid and its related enzymes.
    Fujigaki S; Saito K; Takemura M; Fujii H; Wada H; Noma A; Seishima M
    Arch Biochem Biophys; 1998 Oct; 358(2):329-35. PubMed ID: 9784247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor?
    Kenis G; Prickaerts J; van Os J; Koek GH; Robaeys G; Steinbusch HW; Wichers M
    Int J Neuropsychopharmacol; 2011 Mar; 14(2):247-53. PubMed ID: 20667172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression.
    Raison CL; Dantzer R; Kelley KW; Lawson MA; Woolwine BJ; Vogt G; Spivey JR; Saito K; Miller AH
    Mol Psychiatry; 2010 Apr; 15(4):393-403. PubMed ID: 19918244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
    Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T
    Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis C.
    Evon DM; Esserman DE; Howell MA; Ruffin RA
    Pharmacopsychiatry; 2014 Sep; 47(6):195-201. PubMed ID: 25121993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.